Efficacy and safety of convalescent plasma therapy in SARS‐CoV2 patients on hemodialysis
| Autor: | Venkatesh Arumugam, Tanuj Moses Lamech, Badri Srinivasan Kannan, Kamalakannan Goutham, Shaji Sajmi, Govindasamy Nithya, Paulpandian Vathsalyan, Bhagavatula V R H Sastry, Ravindran Krishna, Dolphin Solomon, Dhanapalan Aiswarya, Ramanathan Sakthirajan, Natarajan Gopalakrishnan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
plasma therapy medicine.medical_treatment Fistula 030232 urology & nephrology Subgroup analysis Disease 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Immune system Renal Dialysis Internal medicine medicine Humans Prospective Studies COVID-19 Serotherapy hemodialysis business.industry SARS-CoV-2 Immunization Passive COVID-19 Hematology Original Articles medicine.disease Thrombosis Treatment Outcome Nephrology RNA Viral Original Article Hemodialysis business Infection COVID 19 chronic kidney disease Cohort study Kidney disease |
| Zdroj: | Hemodialysis International. International Symposium on Home Hemodialysis |
| ISSN: | 1542-4758 1492-7535 |
| Popis: | Background The passive immunization of patients with SARS‐CoV2 with convalescent plasma (CP) is theoretically beneficial in patients with end‐stage renal disease who are immunosuppressed and unable to mount an adequate immune response. Hence, this study was conducted to evaluate the safety and efficacy of CP in patients with chronic kidney disease on hemodialysis with moderate‐to‐severe SARS‐CoV2 infection. Methods A prospective observational cohort study was conducted in consecutive 68 moderate‐to‐severe SARS‐CoV2 infected patients who were on maintenance hemodialysis or with acute worsening of chronic kidney disease which required initiation of hemodialysis. Patients who received CP were compared with those who did not. The primary outcome was death during hospitalization. Clinical characteristics, duration of hospitalization and inflammatory parameters were compared between the two groups. A subgroup analysis was done to find whether early initiation of plasma was associated with better outcome. Results Sixteen patients (44%) in the plasma group and 14 (45%) patients in the control group died during hospitalization (p = 0.95). The median duration of hospitalization was 9 (6–14) days in the plasma group and 9 (6–16) in the control group (p = 0.60). There was no difference in mortality or duration of hospitalization with respect to early initiation of CP (p = 0.29). Fistula thrombosis occurred in two patients (11.1%) in the plasma group. Conclusion Therapy with CP does not appear to confer any clinical benefit in moderate‐to‐severe SARS‐CoV‐2 infected patients with chronic kidney disease on hemodialysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text